Fulgent Genetics investor relations material

Fulgent Genetics, Inc. provides clinical genetic testing services in the United States and internationally. It offers genetic testing services for various types of heredity conditions, such as intellectual disability and movement disorders; infectious diseases, including sexually transmitted infections; pharmacogenetic tests to help individuals determine drug sensitivities; oncology testing services focused on inherited cancer predisposition; prenatal genetic testing for genetic abnormalities; and pediatric and adult behavioral tests for attention deficit hyperactivity disorders. The company also provides COVID-19 testing kits to physicians. In addition, it offers development of customized multi-gene panels for clinical trial recruitment, which are designed for specific panels of genes associated with various genotypes or phenotypes; and PathFinderTG tool that evaluates the likelihood that a patient's symptoms could be caused by an underlying genetic condition. Fulgent Genetics, Inc. was founded in 2011 and is headquartered in Temple City, California.